Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 10, 2003, Pages 1639-1643

  Pal, Manojit ^a   Rao Veeramaneni, Venugopal ^a   Nagabelli, Murali ^a   Rao Kalleda, Srinivas ^a   Misra, Parimal ^a   Rao Casturi, Seshagiri ^a   Rao Yeleswarapu, Koteswar ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYL 3 (4 METHYLSULFONYLPHENYL) 4 PHENYL 2,5 DIHYDRO 2 FURANONE; CYCLOOXYGENASE 2 INHIBITOR; FURANONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONFORMATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION;

EID: 0038363943     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00282-8     Document Type: Article

References (28)

1. Gans K.R., Galbraith W.K., Roman R.J., Haber S.B., Kerr J.S., Schmidt W.K., Smith C., Hewes W.E., AcKerman N.R. J. Pharmacol. Exp. Ther. 254:1990;180.
2. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. Prostaglandins. 47:1994;55.
3. (a) Simon L.S., Lanza F.L., Lipsky P.E., Hubbard R.C., Talwalker S., Schwart B.D., Isakson P.C., Geis G.S. Arthritis Rheum. 41:1998;1591
4. (b) Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Doctor S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Berton E.G., Cogburn J.N., Gregory S.A., Kobolt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., Iaskson P.C. J. Med. Chem. 40:1997;1347.
5. (a) Prasit P., Wang Z., Brideau C., Chan C.-C., Charlson S., Cromlish W., Ether D., Evans J.F., Ford-Hutchinson A.W., Gauthier J.Y., Gordon R., Guay J., Gresser M., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neil G.P., Ouellet M., Percival M.D., Perrier H., Riendeau D., Rodger I., Tagari P., Therien M., Vickers P., Wong E., Xu L.-J., Young R.N., Zamboni R., Boyce S., Rupniak N., Forrest M., Visco D., Patrick D. Bioorg. Med. Chem. Lett. 9:1999;1773
6. (b) Chan C.-C., Boyce S., Brideau C., Charlson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A.W., Forrest M.J., Gauthier J.Y., Gordon R., Gresser M., Guay J., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neil G.P., Ouellet M., Patrick D., Percival M.D., Perrier H., Prasit P., Rodger I., Tagari P., Therien M., Vickers P., Visco D., Wang Z., Webb J., Womg E., Xu L.-J., Young R.N., Zambani R., Riendeau D. J. Pharmacol. Exp. Ther. 290:1999;551.
7. Talley J.J., Brown D.L., Carter J.S., Graneto M.J., Koboldt C.M., Masferrer J.L., Perkins W.E., Rogers R.S., Shaffer A.F., Zhang Y.Y., Zweifel B.S., Seibert K. J. Med. Chem. 43:2000;775.
8. Friesen R.W., Brideau C., Chan C.C., Charleson S., Deschenes D., Dube D., Ethier D., Fortin R., Gauthier J.Y., Girard Y., Gordon R., Greig G.M., Riendeau D., Savoie C., Wang Z., Wong E., Visco D., Xu L.J., Young R.N. Bioorg. Med. Chem. Lett. 8:1998;2777.
9. Riendeau D., Percival M.D., Boyce S., Brideau C., Charlson S., Cromlish W., Ethier D., Evans J., Falgueyret J.-P., Ford-Hutchinson A.W., Gordon R., Greig G., Gresser M., Guay J., Kargman S., Leger S., Mancini J.A., O'Neil G., Ouellet M., Rodger I.W., Therien M., Wang Z., Webb J.K., Wong E., Xu L., Young R.N., Zamboni R., Prasit P., Chan C.-C.B. J. Pharmacol. 121:1997;105.
10. (a) Li C.-S., Black W.C., Brideau C., Chan C.-C., Charlson S., Cromlish W.A., Claveau D., Gauthier J.Y., Gordon R., Greig G., Grimm E., Guay J., Lau C.K., Riendeau D., Therien M., Visco M.D., Wong E., Xu L., Prasit P. Bioorg. Med. Chem. Lett. 9:1999;3181
11. (b) Leblanc Y., Roy P., Boyce S., Brideau C., Chan C.-C., Charlson S., Gordon R., Grimm E., Guay J., Leger S., Li C.S., Riendeau D., Visco D., Wang Z., Webb J., Xu L.J., Prasit P. Bioorg. Med. Chem. Lett. 9:1999;2207.
12. Rahim M.A., Praveen P.N., Knaus E.E. Bioorg. Med. Chem. Lett. 12:1999;2753.
13. Almansa, C.; Alfon, J.; Cavalcanti, F. L.; Gomez, L.; Miralles, A. Presented at the XVIIth International Symposium on Medicinal Chemistry, September 1-5, 2002, Barcelona, Spain.
14. Replacement of methylsulfonyl moiety by other groups including azido bioisostere and their subsequent effect on COX activity has been reported; see, for example: Habeeb A.G., Praveen Rao P.N., Knaus E.E. J. Med. Chem. 44:2001;3039. and references cited therein.
15. Pal, M.; Rao, Y. K.; Rajagopalan, R.; Misra, P.; Kumar, P. M.; Rao, C. S. World Patent WO 01/90097, Nov. 29, 2001; Chem. Abstr. 2002, 136, 5893.
16. Pal, M.; Rao, Y. K.; Rajagopalan, R.; Misra, P.; Kumar, P. M.; Rao, C. S. World Patent WO 01/90097, Nov. 29, 2001; Chem. Abstr. 2002, 136, 5893.
17. (a) Pattabiraman V.R., Padakanti P.S., Veeramaneni V.R., Pal M., Yeleswarapu K.R. Synlett. 2002;947
18. (b) Padakanti S., Veeramaneni V.R., Pattabiraman V.R., Pal M., Yeleswarapu K.R. Tetrahedron Lett. 43:2002;8715
19. (c) Pal M., Rao V.V., Srinivas P., Murali N., Akhila V., Premkumar M., Rao C.S., Misra P., Ramesh M., Rao Y.K. Indian J. Chem. 42B:2003;593
20. (d) Pal, M.; Veeramaneni, V. R., Yeleswarapu, K. R. Presented at the symposium on Current Perspective in Organic Chemistry (CPOC-2002), Indian Association for the Cultivation of Science, Kolkata, India, Jan. 24-25, 2002; Paper number 6.
21. For a similar study on diaryl pyrazoles, see: Bertenshaw S.R., Talley J.T., Rogier D.J., Graneto M.J., Koboldt C.M., Zhang Y. Bioorg. Med. Chem. Lett. 6:1996;2827.
22. Ravikumar K.S., Begue J.-P., Bonnet-Delpon D. Tetrahedron Lett. 39:1998;3141.
23. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., Chan C.-C. Inflamm. Res. 45:1996;68.
24. 523) in COX-2. See: Loung C., Miller A., Barnett J., Chow J., Ramesha C., Browner M.F. Nat. Struct. Biol. 3:1996;927 (b) . These substituents usually confer optimal COX-2 inhibitory potency when one of them is present at the para position of one aryl ring. See: Khanna I.K., Weier R.M., Yu Y., Collins P.W., Miyashiro J.M., Koboldt C.M., Veenhuizen A.W., Currie J.L., Seibert K., Isakson P.C. J. Med. Chem. 40:1997;1619.
25. 523) in COX-2. See: Loung C., Miller A., Barnett J., Chow J., Ramesha C., Browner M.F. Nat. Struct. Biol. 3:1996;927 (b) . These substituents usually confer optimal COX-2 inhibitory potency when one of them is present at the para position of one aryl ring. See: Khanna I.K., Weier R.M., Yu Y., Collins P.W., Miyashiro J.M., Koboldt C.M., Veenhuizen A.W., Currie J.L., Seibert K., Isakson P.C. J. Med. Chem. 40:1997;1619.
26. (a) Leblanc Y., Gauthier J.Y., Ethier D., Guay J., Mancini J., Riendeau D., Tagari P., Vickers P., Wong E., Prasit P. Bioorg. Med. Chem. Lett. 5:1995;2123
27. (b) Therien M., Brideau C., Chan C.C., Cromlish W.A., Gauthier J.Y., Gordon R., Greig G., Kargman S., Lau C.K., Leblanc Y., Li C.-S., O'Neill G.P., Riendeau D., Roy P., Wand Z., Xu L., Prasit P. Bioorg. Med. Chem. Lett. 7:1997;47.
28. 13b generated from 2-(4-methylsulfanylphenyl)acetic acid and appropriate bromoketone (obtained by bromination of 1-phenyl-1-butanone) followed by oxidation of the methylsulfanyl moiety to methanesulfone.